Navigation Links
Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference
Date:5/24/2010

BEIJING, May 24 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today that Mr. Weidong Yin, Chairman, President & CEO, will present at the 2010 UBS Global Specialty Pharmaceuticals Conference, which is being held June 2-3, 2010 in London, England. Sinovac's presentation is scheduled for Wednesday, June 2, 2010 at 10 a.m. BST/5 a.m. Eastern Time.

A live webcast of the presentation will be available online on the Investor Relations Home page of the Sinovac's corporate Web site at http://www.sinovac.com .

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu (TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine, and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

    For more information, please contact:

     Chris Lee
     Sinovac Biotech Ltd.
     Tel:   +86-10-8289-0088 x9659
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

    Investors:
     Amy Glynn/ Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media:
     Janine McCargo
     The Ruth Group
     Tel:   +1-646-536-7033
     Email: jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Reports Unaudited First Quarter 2010 Financial Results
2. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
3. Sinovac Announces Upsizing and Pricing of Common Share Offering
4. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
5. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
6. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
7. Sinovac Reports Unaudited Third Quarter 2009 Financial Results
8. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
9. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
10. Sinovac to Present at 2009 UBS Global Life Sciences Conference
11. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, ... company focused on the licensing, development and commercialization of ... Pharm,s Best Company in North America ... the award based on the FDA approval ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) and ...
(Date:1/20/2017)... ... , ... The two newest companies to join the University City Science Center’s ... from The Wistar Institute, and Sanguis, launched by a trio of students from the ... Vironika is developing a treatment for a chronic viral infection and its associated diseases, ...
(Date:1/20/2017)... Ginkgo Bioworks, the organism company, announced ... the synthesis and assembly of DNA. The acquisition ... synthetic DNA into Ginkgo,s automated organism engineering foundries, ... of new organism designs for application across a ... founded to significantly increase the world,s capacity to ...
Breaking Biology Technology:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/15/2016)...   WaferGen Bio-systems, Inc. (NASDAQ: ... today that on December 13, 2016, it received a ... Stock Market LLC which acknowledged that, as of December ... stock had been at $1.00 or greater for ten ... Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):